Article Details

FDA Approves Genentech's Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L ...

Retrieved on: 2024-09-13 15:10:35

Tags for this article:

Click the tags to see associated articles and topics

FDA Approves Genentech's Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L .... View article details on hiswai:

Excerpt

With Tecentriq Hybreza and Roche/Genentech's 13 other subcutaneous therapies – available across various diseases – we offer additional administration ...

Article found on: www.gene.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up